BioSpace News Archive

Drug Development

FDA Grants Merck’s Keytruda Priority Review for Cervical Cancer

The FDA accepted Merck & Co.’s supplemental Biologics License Application and granted Priority Review for Keytruda in advanced cervical cancer.

March 13, 2018
·
3 min read
·
Mark Terry
Biotech Bay

Are Life Science Companies Falling Behind Tech Companies?

Tech companies have been making significant forays into the life sciences and a new report suggests that life science companies are in danger of falling behind their tech brethren..

March 13, 2018
·
2 min read
·
Mark Terry
Drug Development

Aeglea BioTherapeutics Updates Phase I/II Trial Data

Aeglea BioTherapeutics announced new repeat dose data from its Phase I/II trial of AEB1102 (pegzilarginase) in patients with Arginase 1 Deficiency.

March 13, 2018
·
3 min read
·
Mark Terry
Drug Development

Protalix BioTherapeutics Treatment for Ulcerative Colitis Shows Positive Data

Protalix BioTherapeutics believes it’s on the right track in developing an oral medicine for ulcerative colitis that could potentially replace current TNF-inhibitor therapies that are administered via injection or infusion.

March 13, 2018
·
2 min read
·
Alex Keown
Drug Development

AbbVie’s Elagolix Dazzles in Phase III Trial

AbbVie and Neurocrine Biosciences announced that its Phase III ELARIS UF-II trial of elagolix for uterine fibroids met its primary endpoint.

March 13, 2018
·
2 min read
·
Mark Terry
What’s wrong with being busy? How to work less and accomplish more

What’s wrong with being busy? According to career experts, psychologists and other healthcare providers, and industry leaders, a whole a lot.

March 13, 2018
·
7 min read
Drug Development

Proteostasis Therapeutics Snags Breakthrough Designation

The U.S. Food and Drug Administration granted Proteostasis Therapeutics’ investigational cystic fibrosis add-on therapy the Breakthrough Therapy Designation.

March 13, 2018
·
2 min read
·
Alex Keown
Drug Development

FDA Halts Advaxis Study Following Patient Death

The FDA placed a hold on Advaxis’ Phase I/II trial following the death of a patient.

March 13, 2018
·
2 min read
·
Alex Keown
Business

SanBio Reaches Agreement on Manufacture of Regenerative Medicine Product SB623 with Hitachi Chemical

SanBio Group and Hitachi Chemical Co., Ltd. jointly announced that, through an agreement with Hitachi Chemical Advanced Therapeutics Solutions, LLC, they will manufacture SB623, a proprietary regenerative medicine product under development by SanBio.

March 13, 2018
·
3 min read
Biotech Bay

PASCO Unveils Its New Next Gen Datalogger at NSTA 2018: the SPARK LX

This week at the National Science Teachers Association (NSTA) National Conference in Atlanta, PASCO® will preview its next generation of dataloggers for hands-on, inquiry-based science: the SPARK LX.

March 13, 2018
·
1 min read